MedTrace Logo

Phthalates Exposure in Type 2 Diabetic Patients and Diuretic Therapy

NCT04242758 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2020-01-27

No results posted yet for this study

Summary

In this open clinical trial, 30 subjects with inadequately controlled T2D and eligible, as per good clinical practice, for therapy with SGLT-2 inhibitor, will be randomized to receive a SGLT-2 inhibitor vs other oral-antidiabetic drugs (OADs) therapy for 3 months. Measures will be performed at baseline, after 2 days, after one month and at the end of the study protocol, as per good clinical practice

Conditions

  • Renal Function Disorder
  • Glucose Metabolism Disorders

Interventions

DRUG

Dapagliflozin 10 MG

SGLT2-inhibitor: Diabetic oral drug with diuretic properties

DRUG

Hydrochlorothiazide 12.5mg

Best known thiazide class diuretic.

Sponsors & Collaborators

  • University of Pisa

    lead OTHER

Principal Investigators

  • Anna Solini, Prof · University of Pisa

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-04
Primary Completion
2019-12-30
Completion
2020-04-01

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04242758 on ClinicalTrials.gov